anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study focuses on human exposure to glyphosate, the single most commonly applied agricultural chemical in the world. Glyphosate is an herbicide, and is most commonly known as the active ingredient in "Round Up". Glyphosate has been declared a probable human carcinogen by the International Agency for Research on Cancer and multiple toxicological studies have further suggested potential neurological and developmental effects of glyphosate exposure at environmentally-relevant levels. However, despite its extensive use, frequent presence in food and environmental media, and potential toxicity, current exposure levels in human populations are not well documented. This study aims to assess glyphosate exposure among a cohort of pregnant women and to quantify the relative contribution of agricultural and dietary sources of this exposure. A cohort of 40 pregnant women will be recruited from urban areas \>10 miles from the nearest glyphosate-treated field and agricultural areas \<1 mile from the nearest glyphosate-treated field. Weekly urine samples collected from these women throughout their pregnancies will be used to analyze glyphosate exposure. These same 40 participants will also take part in a two week-long randomized cross-over design dietary intervention, during which participants will receive one week of exclusively organic food (grown without the use of synthetic pesticides, including glyphosate) and one week of exclusively conventional food, in random order. During the intervention, the researchers will collect daily spot urine samples from each participant to analyze glyphosate exposure related to diet. The researchers hypothesize that during the time of year when glyphosate is actively applied, women living near glyphosate-treated fields will have higher exposures than those living further away. They also hypothesize that glyphosate exposure will be reduced among participants during randomization to the organic diet, but that this decrease will be larger among urban women than among those living near glyphosate-treated fields. The researchers have taken extra precautions to eliminate all COVID-specific risks. There will be no face-to-face contact between research staff and study participants throughout the entire study. Interactions between researchers and study participants will take place through videos, emails, texts, and/or phone calls. All urine samples will be left for researchers to pick up at a predetermined location and time, and all groceries will be delivered to participants' home and left at their front door.
Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.

The actions and use of methimazole are similar to those of propylthiouracil. On a weight basis, the drug is at least 10 times as potent as propylthiouracil, but methimazole may be less consistent in action.

Methimazole is readily absorbed from the gastrointestinal tract. It is metabolized rapidly and requires frequent administration. Methimazole is excreted in the urine.

In laboratory animals, various regimens that continuously suppress thyroid function and thereby increase TSH secretion result in thyroid tissue hypertrophy. Under such conditions, the appearance of thyroid and pituitary neoplasms has also been reported. Regimens that have been studied in this regard include antithyroid agents as well as dietary iodine deficiency, subtotal thyroidectomy, implantation of autonomous thyrotropic hormone-secreting pituitary tumors, and administration of chemical goitrogens.
Disclosed is a method for making an antimicrobial material from 1D nanometer silver that does not accumulate in a human body. At first, 1D nanometer silver is mixed in hydrophilic solution to produce 1D nanometer silver solution. Then, adhesive is blended in the 1D nanometer silver solution to produce the antimicrobial material. The antimicrobial material may be used in antimicrobial liquid, antimicrobial dressing or antimicrobial composite. Human skin can easily block the 1D nanometer silver. Therefore, the 1D nanometer silver does not enter or accumulate in the human body. Yet, the antimicrobial material exhibits a high bactericidal rate.
Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.
<P>PROBLEM TO BE SOLVED: To efficiently record a medication history book.  <P>SOLUTION: A CPU 101 specifies and authenticates a prescriptionist by comparing handwritten medication history book image data with the image 162b for specification of personal specifying image data 162 upon inputting the handwritten medication history book image data to a handwriting input device 111 in medication history book recording processing. Upon authenticating the prescriptionist, the medication history book image data is stored on a medication history book data memory 121; a sealing image and a signature image corresponding to the authenticated prescrtiptionist is read from a personal authentication memory 161; and the sealing image and the signature image are corresponded to the medication history book image data for storing on the medication history book image data memory 121. Now, character recognition is applied to the medication history book image data by referring to the image data 121b of the medication history book data memory 121 to transform the medication history book data into character data. The data file of the medication history book data is transmitted to a dispensing pharmacy server 30 from a transmission control section 13.  <P>COPYRIGHT: (C)2004,JPO
The invention comprises compounds of the formula <FORM:1000505/C2/1> and their pharmaceutically acceptable acid addition salts, wherein R is a dialkylamino alkyl, monoalkylamino alkyl, hydroxy alkyl, piperidino alkyl, or morpholino alkyl group. R1 is an aralkyl group of the formula <FORM:1000505/C2/2> <FORM:1000505/C2/3> wherein n is 0 or an integer from 1 to 4, m is an integer from 1 to 4 and R2 to R6 are hydrogen or halogen atoms or alkoxy, nitro, amino, monoalkylamino, dialkylamino, monoacylamino or C1- 5-alkyl groups, and the preparation thereof either by reacting a compound of the formula <FORM:1000505/C2/4> with an alkyl halide R-Hal in the presence of agents capable of splitting off and binding hydrogen halide; or by reacting a compound of the general formula <FORM:1000505/C2/5> with agents capable of oxidizing a secondary alcohol group to a keto group; or by reacting a compound of the general formula <FORM:1000505/C2/6> wherein R8 is halogeno alkyl, with a mono- or dialkyl-amine, piperidine or morpholine.  2 - a  - Hydroxybenzimidazoles are prepared from an N-substituted or -unsubstituted o-phenylene diamine and an appropriate mandelic acid or its imino ether.  2 - a  - Ketobenzimidazoles of Formula V are prepared by oxidation of the corresponding 2-a -hydroxybenzimidazole with selenium dioxide.  Benzimidazoles of Formula VI are prepared from the corresponding 1-hydroxy alkyl derivatives by halogenation. 4-Methoxy phenyl lactic acid nitrile is prepared from anisaldehyde and monochloroacetic acid to form the 4-methoxyphenylacetaldehyde and reacting the bisulphite with a cyanide. The nitrile is converted into the imino ether.  Pharmaceutical compositions, having analgesic and spasmolytic activity, contain the compounds of the invention and may be formulated as tablets, pills, dragees, capsules, suppositories and solutions for parenteral administration.
Systems, devices and methods are provided for titration of a medication dose for a patient or user. The titration may be based on determining a hypoglycemic risk of a user for a plurality of time-of-day periods. The determination of the hypoglycemic risk may be accomplished by known methods, including the glucose pattern analysis, glucose dysregulation analysis, low alarm frequency analysis, and combinations thereof. The system may then select a recommended action based on the analyte pattern type. The system may then store an indicator of the recommended action in a computer memory for output. The system may then output the recommended action. The recommended action may be outputted to the user, an HCP, or a caregiver. The recommended action may also vary depending on who is receiving the recommended action.
OBJECTIVE: The triglyceride glucose (TyG) index is regarded as a reliable alternative indicator for measuring insulin resistance. We investigated the association between the prognosis of patients with subarachnoid hemorrhage (SAH)and the TyG index, explored the potential of the TyG index as a new biomarker for forecasting the outcomes of SAH patients, and explored independent risk factors for predicting the condition of SAH patients.
METHODS: A retrospective analysis was performed of patients who were admitted to a single center due to SAH. Differences in clinical data and correlation between laboratory indexes, disease severity score on admission, and prognosis score were compared between the 2 groups. The study employed multivariate logistic regression analysis to examine the independent influencing aspects of Glasgow Outcome Scale score. The receiver operating characteristic curve was drawn and the area under the curve (AUC) calculated to predict the best cutoff value of the degree of neurological impairment in patients with SAH.
RESULTS: Univariate analysis showed that Glasgow Coma Scale score (86.3% vs. 12.0%, P < 0.001), Hunt-Hess grade (88.2% vs. 15.7%, P < 0.001), white blood cell count (11.20 [7.9, 15.2] vs. 9.1 [7.0, 12.2], P = 0.027), and TyG index (1.49 [1.40, 1.59] vs. 1.16 [1.06, 1.27], P < 0.001) were statistically significantly different. Multivariate analysis showed that TyG index, Hunt-Hess grade, and GCS score were independent risk factors for poor prognosis.
CONCLUSIONS: Patients with SAH may benefit from using the TyG index as a predictive method. In our clinical practice, the TyG index is beneficial for managing diseases and making decisions. More research is required to determine if improved TyG index control would lead to better clinical results in the future.
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are multifactorial disorders that affect the macula and cause significant vision loss. Although inflammation and neoangiogenesis are hallmarks of DME and nAMD, respectively, they share some biochemical mediators. While inflammation is a trigger for the processes that lead to the development of DME, in nAMD inflammation seems to be the consequence of retinal pigment epithelium and Bruch membrane alterations. These pathophysiologic differences may be the key issue that justifies the difference in treatment strategies. Vascular endothelial growth factor inhibitors have changed the treatment of both diseases, however, many patients with DME fail to achieve the established therapeutic goals. From a clinical perspective, targeting inflammatory pathways with intravitreal corticosteroids has been proven to be effective in patients with DME. On the contrary, the clinical relevance of addressing inflammation in patients with nAMD has not been proven yet. We explore the role and implication of inflammation in the development of nAMD and DME and its therapeutical relevance.
Crohn's and ulcerative colitis are common conditions associated with inflammatory bowel disease as well as intestinal flora and epithelial barrier dysfunction. A novel fermented Lactobacillus brevis (AL0035) herein assayed in a trinitro benzene sulfonic acid (TNBS)-induced colitis mice model after oral administration significantly counteracted the body weight loss and improves the disease activity index and histological injury scores. AL0035 significantly decreased the mRNA and protein expression of different pro-inflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-12, IFN-gamma) and enhanced the expression of IL-10. In addition, the probiotic promoted the expression of tight junction proteins, such as ZO-1, keeping the intestinal mucosal barrier function to attenuate colitis symptoms in mice. Markers of inflammation cascade such as myeloperoxidase (MPO) and PPAR-gamma measured in the colon were also modified by AL0035 treatment. AL0035 was also able to reduce different lymphocyte markers' infiltration in the colon (GATA-3, T-Bet, NK1.1) and monocyte chemoattractant protein-1 (MCP-1/CCL2), a key chemokine involved in the migration and infiltration of monocytes/macrophages in the immunological surveillance of tissues and inflammation. In colonic microbiota profile analysis through 16S rRNA sequencing, AL0035 increased the microbial diversity depleted by TNBS administration and the relative abundance of the Lactobacillaceae and Lachnospiraceae families, whereas it decreased the abundance of Proteobacteria. Altogether, these data indicated that AL0035 could lower the severity of colitis induced by TNBS by regulating inflammatory cytokines, increasing the expression of tight junction proteins and modulating intestinal microbiota, thus preventing tissue damage induced by colitis.
FIELD: oral cavity care.SUBSTANCE: inventions relates to a composition for the care of the oral cavity and a method for its preparation. The composition for the care of the oral cavity contains: a) a surfactant system, including: i. at least one nonionic surfactant; ii. at least one anionic surfactant; iii. at least one amphoteric surfactant; b) an agent that increases the foam, which is iota carrageenan, 0.05% of the total weight of the composition; c) a suspending agent, which is high acyl gellan gum, 0.15% of the total weight of the composition; d) an orally acceptable liquid carrier. Wherein, the specified surfactant system includes sodium lauryl sarcosinate, lauryl glucoside and cocamidopropyl betaine in a ratio of 40:40:20 and the content of the surfactant system is 1.0% of the total weight of the composition. The method for preparing the composition for caring for the oral cavity includes the following steps: a) adding the above mixture of surfactants, b) adding a suspending agent and an agent that increases foaming, c) mixing a mixture of surfactants, a suspending agent and an agent that increases foaming, with an acceptable for the oral cavity liquid carrier until smooth.EFFECT: combination of the above components provides the formation of a foam with characteristics comparable to those of a composition containing a blowing agent; the use of the composition provides sufficient lather even after spitting, swallowing, or otherwise removing it from the mouth by the formation of foam that remains in the mouth as a thin layer covering the teeth, tongue or other surfaces of the mouth.2 cl, 14 tbl, 6 ex
INTRODUCTION: The objective of this study was to identify and clinically characterize patients treated in an Otoneurology Unit who experienced vestibular ototoxicity as a result of using aminoglycoside ear drops during outbreaks of superinfection in chronic otitis media.
MATERIAL AND METHODS: An observational retrospective study was conducted, including patients with perforated eardrums who developed vestibular ototoxicity within the past 10 years following the application of topical ear aminoglycosides in a tertiary referral center. The study encompassed the assessment of the clinical presentation, treatment, quality of life, and evolution after treatment of the identified individuals.
RESULTS: During the study period, 6 patients, aged between 33 and 71 years, developed vestibular ototoxicity following the use of topical aminoglycoside drops due to infection flares in chronic otitis media. All cases involved the use of gentamicin. Two cases were unilateral, and 4 were unilateral. The onset of symptoms occurred within one to four weeks of using the drops, resulting in all patients experiencing instability without vertigo attacks. After discontinuing the drops and undergoing vestibular rehabilitation, 4 patients experienced sequelae, with 2 patients (both with bilateral vestibular hypofunction) suffering significant impairment in their quality of life.
CONCLUSIONS: Vestibular ototoxicity due to the topical application of aminoglycosides during acute exacerbations of chronic otitis media is a rare occurrence. However, given its potential for severe consequences and the fact that we are still encountering patients with this condition, healthcare professionals should explore alternative antibacterial agents that offer similar efficacy.
Rheumatoid arthritis (RA) is a long-term inflammatory disease which commonly occurs in the small joints of the hands, wrists and feet leading to swelling, pain and stiffness in the affected joints. The condition is two to three times more prevalent in women than in men. Although it might occur at any age, the incidence of the disease is highest between the ages of 40 and 65 years. Currently, there is no treatment that provides complete remission of the disease for people living with RA. Treatment of RA aims to reduce the symptoms and improve the health of the patient. Although diet is not part of the mainstream treatment, many studies have reported beneficial effects of certain diets on RA symptoms. The MEDRA study will examine the habitual dietary intakes of people living with RA in Ireland and will explore whether people with RA will benefit from either a Mediterranean dietary pattern or the Healthy eating guidelines in Ireland. This small scale study will provide useful information on whether people with RA in Ireland can adhere to a Mediterranean dietary pattern and whether the intervention will have beneficial impact on the physical function and quality of life. This is important work prior to proceeding to larger intervention studies.
BACKGROUND: Hip fractures in older adults are common and carry a high risk of morbidity and mortality. Preoperative dehydration, a key risk factor for adverse outcomes, is often underdiagnosed at admission. It is important to identify high risk patients and optimize modifiable risk factors to improve the postoperative outcome. The p-POSSUM Score is a useful predictor of postoperative mortality risk. Implementing a defined fluid resuscitation protocol early in high-risk groups has proven effective in reducing both postoperative morbidity and mortality.
MATERIALS AND METHODS: We conducted a single-center, retrospective quality improvement study at a Level 1 trauma center in Switzerland, focusing on geriatric patients over 70 with a p-POSSUM Score > 5% and a proximal femur fracture, undergoing surgery between February 2015 and September 2019. We hypothesized that our institutional goal-directed fluid resuscitation protocol (GDT) would result in lower 30- and 90-day mortality rates and fewer complications for these high-risk patients. Outcome changes over time were analyzed annually.
RESULTS: 312 patients were included in our study. 147 followed our institutional GDT protocol, while 165 patients received standard care and were used as a control group. Initially, the odds ratio (OR) for 30-days mortality favored the GDT group; 2015 0.30 (CI: 0.07-1.18), 2016 0.28 (CI: 0.07-1.07), 2017 0.51 (CI: 0.13-2.04). This shifted toward the Non-GDT group in the year 2018 with a OR of 2.14 (CI: 0.59-7.84) and 2019 with 1.92 (CI 0.47-7.83). The pattern for 90-day mortality results was similar and slightly more pronounced. The estimates for the odds ratios remained consistent even after adjustment for the p-POSSUM score. The relative frequencies of complications showed no remarkable differences between the groups (GDT vs. Non-GDT).
CONCLUSION: In our study, the treatment according to our GDT protocol was associated with survival advantage in the first three years. However, this trend reversed in 2018, with Non-GDT patients faring better. Although our retrospective study does not provide enough evidence of causality between the protocol and the mortality rates, it revealed that continuous critical evaluation of internal processes is essential in healthcare for quality management. This allows timely identification and adaptation of processes to issues, especially after initially positive results.
PURPOSE: A nanoporous membrane with nanopores, which is a depot system capable of controlling the release of functional proteins in cosmetics is provided to be used as a nanoporous carrier based on a block copolymer. CONSTITUTION: A nanoporous membrane is prepared using PS-b-PMMA[polystyrene-block-poly (methyl methacrylate) polymers. The particle size of nanopores of the nanoporous membrane is 10-20 nm. The average of the particle size is 15 nm. A method for delivering antibody-based proteins constantly maintains release rate using the nanoporous membrane. The nanoporous membrane is used in a sustained release drug delivery system of the antibody-based proteins.
<P>PROBLEM TO BE SOLVED: To obtain a hair dye composition capable of suppressing a sensitizing property.  <P>SOLUTION: This hair dye composition comprises (A) a direct dye and (B) a monoterpene-based hydrocarbon. The component B is preferably a cyclic monoterpene. The cyclic monoterpene is preferably at least one kind of compound selected from pinene, terpinene and limonene. The terpinene is preferably at least one kind of compound selected from α-terpinene and γ-terpinene. Both of the α-terpinene and the γ-terpinene are preferably contained in the hair dye composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and/or Islet 1+/FGFR3+ ventricular progenitor cells and/or Islet 1+/LIFR+/FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and/or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.